TDMS Study 05181-04 Pathology Tables
NTP Experiment-Test: 05181-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TETRAHYDROFURAN Date: 02/21/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 12:11:24
CORE STUDY
Facility: Battelle Northwest
Chemical CAS #: 0109-99-9
Lock Date: 03/24/93
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05181-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TETRAHYDROFURAN Date: 02/21/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 12:11:24
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 200 PPM 600 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Accidently Killed 5 1 1
Moribund Sacrifice 13 10 20 13
Natural Death 3 6 3 5
Survivors
Terminal Sacrifice 29 33 26 32
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Duodenum (45) (44) (46) (46)
Intestine Small, Jejunum (45) (44) (46) (46)
Carcinoma 1 (2%)
Polyp Adenomatous 1 (2%)
Intestine Small, Ileum (46) (45) (46) (46)
Liver (50) (50) (50) (48)
Carcinoma, Metastatic, Islets, Pancreatic 1 (2%)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma 4 (8%) 6 (12%) 9 (18%) 10 (21%)
Hepatocellular Carcinoma, Multiple 2 (4%) 4 (8%) 1 (2%) 6 (13%)
Hepatocellular Adenoma 10 (20%) 14 (28%) 13 (26%) 19 (40%)
Hepatocellular Adenoma, Multiple 2 (4%) 3 (6%) 5 (10%) 12 (25%)
Hepatocholangiocarcinoma 1 (2%) 1 (2%)
Hepatocholangiocarcinoma, Multiple 1 (2%)
Histiocytic Sarcoma 3 (6%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Mesentery (6) (9) (9) (9)
Carcinoma, Metastatic, Islets, Pancreatic 1 (11%)
Carcinoma, Metastatic, Ovary 1 (11%)
Fibrous Histiocytoma 1 (11%)
Hemangiosarcoma 1 (11%) 1 (11%)
Histiocytic Sarcoma 1 (17%) 1 (11%)
Sarcoma 1 (17%)
Oral Mucosa (1)
Squamous Cell Carcinoma 1 (100%)
Pancreas (48) (49) (48) (46)
Carcinoma, Metastatic, Islets, Pancreatic 1 (2%)
Carcinoma, Metastatic, Ovary 1 (2%)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Histiocytic Sarcoma 1 (2%)
Salivary Glands (50) (50) (50) (48)
Stomach, Forestomach (50) (49) (49) (47)
Page 2
NTP Experiment-Test: 05181-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TETRAHYDROFURAN Date: 02/21/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 12:11:24
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 200 PPM 600 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Squamous Cell Papilloma 1 (2%) 2 (4%)
Stomach, Glandular (49) (48) (48) (47)
Carcinoma, Metastatic, Ovary 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (48)
Hemangiosarcoma 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (46)
Adrenal Medulla (49) (49) (50) (45)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 1 (2%) 2 (4%)
Islets, Pancreatic (48) (49) (47) (46)
Carcinoma 1 (2%)
Pituitary Gland (47) (48) (48) (48)
Pars Distalis, Adenoma 10 (21%) 8 (17%) 14 (29%) 8 (17%)
Pars Intermedia, Adenoma 1 (2%) 1 (2%)
Thyroid Gland (50) (50) (49) (47)
C-Cell, Adenoma 1 (2%)
C-Cell, Carcinoma 2 (4%)
Follicular Cell, Adenoma 2 (4%) 1 (2%) 3 (6%) 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (49) (50) (50) (46)
Carcinoma 1 (2%)
Carcinoma, Metastatic, Islets, Pancreatic 1 (2%)
Cystadenoma 2 (4%) 1 (2%)
Histiocytic Sarcoma 2 (4%)
Teratoma Benign 1 (2%)
Uterus (49) (50) (49) (49)
Adenoma 1 (2%)
Carcinoma, Metastatic, Ovary 1 (2%)
Page 3
NTP Experiment-Test: 05181-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TETRAHYDROFURAN Date: 02/21/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 12:11:24
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 200 PPM 600 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Deciduoma Benign 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Polyp Stromal 1 (2%) 4 (8%) 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (50) (49) (46)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 2 (4%)
Sarcoma 1 (2%)
Lymph Node (5) (4) (4) (2)
Renal, Histiocytic Sarcoma 1 (20%)
Lymph Node, Bronchial (36) (41) (39) (41)
Carcinoma, Metastatic, Islets, Pancreatic 1 (2%)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (3%)
Lymph Node, Mandibular (40) (41) (39) (41)
Hemangioma 1 (3%)
Lymph Node, Mesenteric (45) (46) (47) (45)
Carcinoma, Metastatic, Islets, Pancreatic 1 (2%)
Carcinoma, Metastatic, Ovary 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Lymph Node, Mediastinal (37) (36) (41) (38)
Carcinoma, Metastatic, Islets, Pancreatic 1 (3%)
Carcinoma, Metastatic, Ovary 1 (2%)
Fibrous Histiocytoma, Metastatic, Mesentery 1 (3%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (3%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%)
Spleen (49) (50) (49) (46)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Thymus (40) (44) (38) (44)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (48) (49) (50) (50)
Carcinoma 1 (2%) 1 (2%)
Skin (49) (50) (50) (50)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%) 3 (6%)
Subcutaneous Tissue, Sarcoma, Metastatic,
Mesentery 1 (2%)
Page 4
NTP Experiment-Test: 05181-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TETRAHYDROFURAN Date: 02/21/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 12:11:24
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 200 PPM 600 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (49)
Hemangiosarcoma 1 (2%)
Osteosarcoma 1 (2%) 1 (2%) 2 (4%)
Skeletal Muscle (2) (1)
Carcinoma, Metastatic, Islets, Pancreatic 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (49)
Histiocytic Sarcoma 2 (4%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (49)
Alveolar/Bronchiolar Adenoma 1 (2%) 2 (4%) 3 (6%) 3 (6%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 1 (2%) 2 (4%) 2 (4%)
Carcinoma, Metastatic, Ovary 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 5 (10%) 3 (6%) 3 (6%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Histiocytic Sarcoma 3 (6%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Mediastinum, Fibrous Histiocytoma,
Metastatic, Mesentery 1 (2%)
Mediastinum, Hemangiosarcoma 1 (2%)
Mediastinum, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (4) (2) (2) (1)
Adenoma 2 (50%) 1 (50%) 2 (100%) 1 (100%)
Carcinoma 1 (50%)
____________________________________________________________________________________________________________________________________
Page 5
NTP Experiment-Test: 05181-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TETRAHYDROFURAN Date: 02/21/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 12:11:24
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 200 PPM 600 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (49) (49) (46)
Carcinoma, Metastatic, Ovary 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 3 (6%)
Urinary Bladder (47) (48) (47) (45)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 3 (6%) 2 (4%)
Lymphoma Malignant 7 (14%) 2 (4%) 4 (8%) 5 (10%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05181-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TETRAHYDROFURAN Date: 02/21/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 12:11:24
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 200 PPM 600 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 34 38 41 44
Total Primary Neoplasms 58 59 74 83
Total Animals with Benign Neoplasms 21 29 31 37
Total Benign Neoplasms 32 38 49 48
Total Animals with Malignant Neoplasms 21 18 21 28
Total Malignant Neoplasms 26 21 25 35
Total Animals with Metastatic Neoplasms 3 6 5 5
Total Metastatic Neoplasm 4 20 12 9
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 05181-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TETRAHYDROFURAN Date: 02/21/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 12:11:24
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 200 PPM 600 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 7 7 4 14
Moribund Sacrifice 11 12 18 24
Survivors
Terminal Sacrifice 32 31 28 12
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (42) (46) (44) (38)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Intestine Small, Jejunum (45) (45) (46) (37)
Carcinoma 1 (2%) 1 (2%) 1 (3%)
Intestine Small, Ileum (46) (46) (46) (40)
Liver (50) (50) (50) (50)
Cholangiocarcinoma 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%) 2 (4%)
Hepatocellular Carcinoma 10 (20%) 9 (18%) 8 (16%) 5 (10%)
Hepatocellular Carcinoma, Multiple 4 (8%) 4 (8%) 6 (12%) 4 (8%)
Hepatocellular Adenoma 19 (38%) 14 (28%) 14 (28%) 9 (18%)
Hepatocellular Adenoma, Multiple 5 (10%) 5 (10%) 2 (4%) 5 (10%)
Hepatocholangiocarcinoma 3 (6%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mesentery (3) (3) (2)
Cholangiocarcinoma, Metastatic, Liver 1 (33%)
Hemangioma 1 (50%)
Hemangiosarcoma 1 (33%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (33%)
Pancreas (48) (48) (46) (48)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Salivary Glands (50) (50) (50) (50)
Tooth (1) (2)
Odontoma 1 (50%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (49) (50) (50) (50)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Hemangiosarcoma 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05181-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TETRAHYDROFURAN Date: 02/21/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 12:11:24
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 200 PPM 600 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (48) (50) (49) (50)
Adenoma 3 (6%) 1 (2%)
Adrenal Medulla (48) (50) (49) (50)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Islets, Pancreatic (48) (48) (46) (48)
Adenoma 1 (2%)
Pituitary Gland (45) (47) (45) (47)
Pars Distalis, Adenoma 1 (2%) 1 (2%)
Thyroid Gland (49) (50) (49) (49)
Follicular Cell, Adenoma 4 (8%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (49) (50) (50) (50)
Carcinoma, Metastatic, Lung 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sarcoma 1 (2%)
Preputial Gland (50) (49) (50) (48)
Prostate (48) (43) (44) (47)
Seminal Vesicle (48) (48) (46) (46)
Sarcoma 1 (2%)
Testes (50) (50) (50) (50)
Hemangioma 1 (2%)
Interstitial Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Lymph Node, Bronchial (33) (32) (36) (26)
Carcinoma, Metastatic, Lung 1 (3%)
Cholangiocarcinoma, Metastatic, Liver 1 (3%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%)
Lymph Node, Mesenteric (47) (48) (46) (41)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mediastinal (36) (40) (39) (32)
Cholangiocarcinoma, Metastatic, Liver 1 (3%)
Hepatocholangiocarcinoma, Metastatic, Liver 2 (6%)
Page 9
NTP Experiment-Test: 05181-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TETRAHYDROFURAN Date: 02/21/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 12:11:24
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 200 PPM 600 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Spleen (48) (49) (47) (49)
Hemangiosarcoma 1 (2%)
Thymus (35) (37) (34) (36)
Cholangiocarcinoma, Metastatic, Liver 1 (3%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (47) (50) (48) (50)
Prepuce, Sarcoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma, Metastatic,
Epididymis 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Skeletal Muscle (2) (1)
Cholangiocarcinoma, Metastatic, Liver 1 (100%)
Hepatocholangiocarcinoma, Metastatic, Liver 2 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (48) (49) (48) (48)
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 16 (32%) 6 (12%) 7 (14%) 4 (8%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (4%) 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 6 (12%) 9 (18%) 6 (12%) 3 (6%)
Carcinoma 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Hemangiosarcoma, Metastatic, Skin 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 1 (2%) 3 (6%)
Hepatocholangiocarcinoma, Metastatic, Liver 2 (4%) 1 (2%)
Mediastinum, Hemangiosarcoma 1 (2%)
Mediastinum, Hepatocholangiocarcinoma,
Metastatic, Liver 2 (4%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 05181-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TETRAHYDROFURAN Date: 02/21/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 12:11:24
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 200 PPM 600 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (4) (4) (4) (3)
Adenoma 1 (25%) 3 (75%) 3 (75%) 1 (33%)
Carcinoma 3 (75%) 1 (33%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (50) (49) (50)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Renal Tubule, Adenoma 1 (2%)
Urinary Bladder (48) (49) (46) (48)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymphoma Malignant 2 (4%) 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 05181-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TETRAHYDROFURAN Date: 02/21/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 12:11:24
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 200 PPM 600 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 47 39 44 21
Total Primary Neoplasms 86 61 61 36
Total Animals with Benign Neoplasms 36 27 26 17
Total Benign Neoplasms 54 31 32 21
Total Animals with Malignant Neoplasms 24 25 26 12
Total Malignant Neoplasms 32 30 29 15
Total Animals with Metastatic Neoplasms 4 3 5 1
Total Metastatic Neoplasm 17 12 6 1
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------